Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?

Bone Marrow Transplantation volume 44, pages 331–332 (2009)Cite this article

Dasatinib, a novel protein tyrosine kinase inhibitor targeting Src family kinases (for example, Lyn, Fyn, Hck) and Abl family kinases, was recently approved for treatment of adult patients with CML, resistant or intolerant to imatinib.1 It potently inhibits the constitutively active BCR–ABL kinase, but also Lck at low picomolar concentrations.2 Recently it was reported that dasatinib specifically targets the earliest events in TCR signaling and enhances the inhibitory effects of CYA, and was thus proposed as a new therapeutic opportunity to address autoimmune diseases, GVHD and transplant allograft rejection.3

We report here a Ph+ CML patient who had relapsed at the molecular level after haploidentical BMT with chronic liver GVHD, who was resistant and intolerant to high-dose imatinib, and in whom a low dose of dasatinib restored the molecular response and improved the hepatic dysfunction due to GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hochhaus A, Baccarani M, Deininger M, Apperley J, Lipton JH, Goldberg SL et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukaemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200–1206.

    Article  CAS  PubMed  Google Scholar 

  2. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J . Important therapeutic targets in chronic myelogenous leukaemia. Clin Cancer Res 2007; 13: 1089–1097.

    Article  CAS  PubMed  Google Scholar 

  3. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366–1377.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Seggewiss R, Lorè K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–2479.

    Article  CAS  PubMed  Google Scholar 

  5. Ball LM, Egeler RM, EBMT Paediatric Working Party. Acute GVHD: pathogenesis and classification. Bone Marrow Transplant 2008; 41 (Suppl 2): S58–S64.

    Article  CAS  PubMed  Google Scholar 

  6. Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukaemia antigens. Exp Hematol 2008; 36: 1297–1308.

    Article  CAS  PubMed  Google Scholar 

  7. Mustjoki S, Ekblom M, Petteri Arstila T, Dybedal I, Epling-Burnette PK, Garzon F et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Blood 2008; 112: 215 (Abstract no. 573).

    Article  Google Scholar 

  8. Nam S, Wiliams A, Vultur A, List A, Bhalla K, Smith D et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukaemia cells. Mol Cancer Ther 2007; 6: 1400–1405.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy

    M Breccia, L Cannella, C Stefanizzi, M Santopietro & G Alimena

  2. Department of Clinical and Experimental Medicine, Hematopoietic Stem Cell Transplant Unit, Section of Hematology and Immunology, University of Perugia, Perugia, Italy

    A Carotti

Authors
  1. M Breccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Cannella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Stefanizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Carotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Santopietro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Alimena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Breccia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breccia, M., Cannella, L., Stefanizzi, C. et al. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect?. Bone Marrow Transplant 44, 331–332 (2009). https://doi.org/10.1038/bmt.2009.20

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.20

This article is cited by

Search

Advanced search

Quick links